Sustainability | October 14, 2022
JB Pharma publishes its maiden sustainability report
Since FY 2020 till FY 2022, the organisation has reduced energy consumption by 9.2%
Since FY 2020 till FY 2022, the organisation has reduced energy consumption by 9.2%
Our strategy to drive therapy and brand-focused expansion will continue to show results, especially in the domestic business.
JB Pharma is the fastest growing pharmaceutical company in FY 2021-22 and Q1 of FY 2022-23.
Profit after Tax stood at Rs. 105 crore as compared to Rs. 119 crore on account of higher treasury income in Q1 FY22, non-cash ESOP cost, depreciation on account of acquired brands and finance costs in Q1 FY23
Health resources – both human and material are precious assets to the society and a robust health care administration and management system ensures their effective utilization: Dr Bharati Pravin Pawar
The total covered market size of four brands – Z&D, Pediclory, Pecef & Ezinapi combined is Rs 1800 crores
ANI’s Clorazepate Dipotassium Tablets are the generic version of the Reference Listed Drug (RLD) Tranxene.
Operations at Oakville, Canada manufacturing plant expected to end by first quarter 2023
JB, in its new avatar, emerges as the fastest growing pharmaceuticals company in India
The funding will enable the company to expand into the segment of HealthCare Service offerings, both in terms of geography and operations
Subscribe To Our Newsletter & Stay Updated
